Post by kickingfrog on Jan 30, 2011 16:00:35 GMT
Maltodextrins
Opinion of the Scientific Panel on Dietetic Products, Nutrition and Allergies
on a request from the Commission related to a notification from AAC on wheat-based maltodextrins
pursuant to Article 6, paragraph 11 of
Directive 2000/13/EC
(Request Nº EFSA-Q-2006-163)
(adopted on 3 May 2007)
…
3.3.1 Coeliac disease
A new DBPCFC was provided by the applicant involving 90 adult patients with a biopsy-based diagnosis of coeliac disease. Patients were challenged with either wheat starch-based maltodextrin (n = 30), glucose syrup (n = 30) or placebo (n = 30) daily for 24 weeks. Patients with refractory coeliac disease or with dietary transgressions had been excluded. Assessment was accomplished by clinical evaluation, dietary and laboratory analyses, telephone assessment and initially and ultimately a small intestinal biopsy. Differences between baseline and end of study were indicated by delta values. Daily ingestion of wheat starch-based maltodextrin did not have any deleterious effect on the small bowel mucosa. Differences in small intestinal villous height by crypt depth ratio and density of intraepithelial lymphocytes were not statistically significant. The same was observed for gastrointestinal symptoms, quality of life and laboratory parameters.
There were eight drop-outs, seven due to abdominal symptoms, one to non-compliance. None of those patients developed villous atrophy. Three of those drop-outs belonged to the maltodextrin group, three to the placebo group, and two to the glucose syrup group.
Minor dietary lapses were observed in six out of 90 patients. One of those patients belonged to the maltodextrin group, one to the placebo group. Eighty-six out of 90 patients (including drop-outs) consented to a final biopsy and full evaluation.
It is concluded by the applicant that there was no adverse effect of the maltodextrin preparation used over a 24-week challenge in 27 fully evaluated adult Finnish coeliac patients. …
www.efsa.europa.eu/en/efsajournal/doc/nda_op_ej487_wheat_based_maltodextrins_aac_en.pdf.pdf
*********************************************
Glucose syrups, dextrose and maltodextrins are GF
8(10):1240-8. Epub 2008 Aug 17.
Clinical trial: gluten microchallenge with wheat-based starch hydrolysates in coeliac disease patients - a randomized, double-blind, placebo-controlled study to evaluate safety.
Kaukinen K, Salmi T, Collin P, Huhtala H, Kärjä-Lahdensuu T, Mäki M.
Department of Gastroenterology and Alimentary Tract Surgery, Tampere University Hospital, and Medical School, University of Tampere, Tampere, Finland.
BACKGROUND: Wheat-based starch hydrolysates such as glucose syrups, dextrose and maltodextrins are found in more than 50% of European processed food. These products contain low amounts of residual gluten and it has been questioned whether they are safe for coeliac disease patients.
AIM: To investigate whether coeliac disease patients can safely consume wheat-based starch hydrolysate products.
METHODS: This randomized, double-blind, placebo-controlled, prospective follow-up study involved 90 coeliac disease patients in remission randomized to consume glucose syrups, maltodextrins or placebo for 24 weeks. Small bowel mucosal morphology and inflammation, symptoms, coeliac serology and malabsorption laboratory data were evaluated at baseline and at the end of the study.
RESULTS: Daily ingestion of wheat-based starch hydrolysates, glucose syrups and maltodextrins, had no deleterious effect on small-bowel mucosal villous architecture or inflammation in coeliac disease patients when compared to the placebo group. Neither were there any significant differences in gastrointestinal symptoms, serology or malabsorption parameters after 24 weeks.
CONCLUSIONS: Wheat-based starch hydrolysates, glucose syrups and maltodextrins did not have harmful effect on coeliac disease patients. Coeliac patients can thus safely continue to consume these products.
PMID: 18710436 [PubMed - indexed for MEDLINE]
****************************************
Opinion of the Scientific Panel on Dietetic Products, Nutrition and Allergies
on a request from the Commission related to a notification from AAC on wheat-based maltodextrins
pursuant to Article 6, paragraph 11 of
Directive 2000/13/EC
(Request Nº EFSA-Q-2006-163)
(adopted on 3 May 2007)
…
3.3.1 Coeliac disease
A new DBPCFC was provided by the applicant involving 90 adult patients with a biopsy-based diagnosis of coeliac disease. Patients were challenged with either wheat starch-based maltodextrin (n = 30), glucose syrup (n = 30) or placebo (n = 30) daily for 24 weeks. Patients with refractory coeliac disease or with dietary transgressions had been excluded. Assessment was accomplished by clinical evaluation, dietary and laboratory analyses, telephone assessment and initially and ultimately a small intestinal biopsy. Differences between baseline and end of study were indicated by delta values. Daily ingestion of wheat starch-based maltodextrin did not have any deleterious effect on the small bowel mucosa. Differences in small intestinal villous height by crypt depth ratio and density of intraepithelial lymphocytes were not statistically significant. The same was observed for gastrointestinal symptoms, quality of life and laboratory parameters.
There were eight drop-outs, seven due to abdominal symptoms, one to non-compliance. None of those patients developed villous atrophy. Three of those drop-outs belonged to the maltodextrin group, three to the placebo group, and two to the glucose syrup group.
Minor dietary lapses were observed in six out of 90 patients. One of those patients belonged to the maltodextrin group, one to the placebo group. Eighty-six out of 90 patients (including drop-outs) consented to a final biopsy and full evaluation.
It is concluded by the applicant that there was no adverse effect of the maltodextrin preparation used over a 24-week challenge in 27 fully evaluated adult Finnish coeliac patients. …
www.efsa.europa.eu/en/efsajournal/doc/nda_op_ej487_wheat_based_maltodextrins_aac_en.pdf.pdf
*********************************************
Glucose syrups, dextrose and maltodextrins are GF
8(10):1240-8. Epub 2008 Aug 17.
Clinical trial: gluten microchallenge with wheat-based starch hydrolysates in coeliac disease patients - a randomized, double-blind, placebo-controlled study to evaluate safety.
Kaukinen K, Salmi T, Collin P, Huhtala H, Kärjä-Lahdensuu T, Mäki M.
Department of Gastroenterology and Alimentary Tract Surgery, Tampere University Hospital, and Medical School, University of Tampere, Tampere, Finland.
BACKGROUND: Wheat-based starch hydrolysates such as glucose syrups, dextrose and maltodextrins are found in more than 50% of European processed food. These products contain low amounts of residual gluten and it has been questioned whether they are safe for coeliac disease patients.
AIM: To investigate whether coeliac disease patients can safely consume wheat-based starch hydrolysate products.
METHODS: This randomized, double-blind, placebo-controlled, prospective follow-up study involved 90 coeliac disease patients in remission randomized to consume glucose syrups, maltodextrins or placebo for 24 weeks. Small bowel mucosal morphology and inflammation, symptoms, coeliac serology and malabsorption laboratory data were evaluated at baseline and at the end of the study.
RESULTS: Daily ingestion of wheat-based starch hydrolysates, glucose syrups and maltodextrins, had no deleterious effect on small-bowel mucosal villous architecture or inflammation in coeliac disease patients when compared to the placebo group. Neither were there any significant differences in gastrointestinal symptoms, serology or malabsorption parameters after 24 weeks.
CONCLUSIONS: Wheat-based starch hydrolysates, glucose syrups and maltodextrins did not have harmful effect on coeliac disease patients. Coeliac patients can thus safely continue to consume these products.
PMID: 18710436 [PubMed - indexed for MEDLINE]
****************************************